Clinical Testing News and Research

RSS

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

7 Oct 2009

Spinal fusion dynamic stabilization system manufacturers ordered to conduct postmarket surveillance studies

The U.S. Food and Drug Administration today ordered manufacturers of certain types of pedicle screw systems, called dynamic stabilization systems, to conduct postmarket surveillance studies to collect clinical data on a number of potential safety issues, including fusion rates and frequency of additional surgeries.

6 Oct 2009

Inviragen, SingVax merge their complementary vaccine pipelines

Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that is developing a wide range of vaccines for infectious diseases prevalent in emerging economies.

6 Oct 2009

IBM scientists to build nanoscale DNA sequencer to read human DNA

In an effort to build a nanoscale DNA sequencer, IBM scientists are drilling nano-sized holes in computer-like chips and passing DNA strands through them in order to read the information contained within their genetic code.

6 Oct 2009

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV.

5 Oct 2009

$7.2 million grant awarded to develop microbicide-releasing vaginal ring

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a four-year, $7.2 million grant to develop a microbicide-releasing vaginal ring to prevent HIV transmission.

3 Oct 2009

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.

1 Oct 2009

Phase 1 clinical trial to test safety and activity of human MAB launched in India

MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus.

1 Oct 2009

New recommendations for strengthening oversight of laboratory-developed tests

The College of American Pathologists today announced new recommendations for strengthening oversight of laboratory-developed tests (LDTs), proposing a three-tier 'risk-based' system that would protect patients by ensuring every laboratory developed test is reported to an oversight body, and instituting a graduated system of review based on a test's potential risk to patients.

25 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

StemCells to take part in international networking event

StemCells, Inc. (NASDAQ:STEM) announced today its participation in the 2009 World Stem Cell Summit to be held September 21 – 23 in Baltimore, Maryland.

22 Sep 2009

Mild exercises for the bed-bound patients helps to combat muscle wasting

Critical care experts at Johns Hopkins are reporting initial success in boosting recovery and combating muscle wasting among critically ill, mostly bed-bound patients using any one of a trio of mild physical therapy exercises during their stays in the intensive care unit (ICU).

22 Sep 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

21 Sep 2009

Bioniche announces fiscal 2009 year-end results

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

19 Sep 2009

BioCision's partnership with Therapak for distributing its products in clinical market

BioCision LLC, the CoolRack company, today announced that it has entered into an agreement with Therapak Corporation for the distribution of BioCision’s products into the clinical market. The deal marks BioCision’s first distribution agreement for the clinical market and expands its access to clinical settings across the United States and Europe.

16 Sep 2009

NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process

Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million.

16 Sep 2009

KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring agent.

15 Sep 2009

FDA clearance for PRO-STIM bone graft substitute

Wright Medical Group, Inc., a global orthopaedic medical device company, today announced the 510K clearance of PRO-STIM™ Injectable Osteoinductive Bone Graft Substitute. PRO-STIM™ graft is a composite grafting material that is injected through a small needle, hardens, and is replaced by the patient’s new bone over time.

14 Sep 2009

CDI and VivoMedica launch pharmaceutical industry consortium

Cellular Dynamics International (CDI) and VivoMedica plc announce the launch of CARDIOTOX - a pharmaceutical industry consortium to validate a human cell model and analysis system for preclinical cardiotoxicity testing of pharmaceutical candidate compounds.

14 Sep 2009

NIH provides Inviragen second major grant to develop a dengue vaccine

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.

10 Sep 2009

Clinical Testing News and Research

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Spinal fusion dynamic stabilization system manufacturers ordered to conduct postmarket surveillance studies

Inviragen, SingVax merge their complementary vaccine pipelines

IBM scientists to build nanoscale DNA sequencer to read human DNA

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

$7.2 million grant awarded to develop microbicide-releasing vaginal ring

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Phase 1 clinical trial to test safety and activity of human MAB launched in India

New recommendations for strengthening oversight of laboratory-developed tests

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

StemCells to take part in international networking event

Mild exercises for the bed-bound patients helps to combat muscle wasting

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche announces fiscal 2009 year-end results

BioCision's partnership with Therapak for distributing its products in clinical market

NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process

KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent

FDA clearance for PRO-STIM bone graft substitute

CDI and VivoMedica launch pharmaceutical industry consortium

NIH provides Inviragen second major grant to develop a dengue vaccine

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News